Skip to main content
Find a DoctorGet Care Now
Skip to main content
Search

Contrast

Contact

Share

Donate

MyChart

Help

Lawrence + Memorial Hospital using precision medicine to treat breast cancer

Wednesday, October 13, 2021

NEW LONDON, CT (Oct. 13, 2021) Yale New Haven Health is bringing precision medicine to breast cancer patients at Lawrence + Memorial Hospital (L+M) with a new imaging agent that is designed specifically to detect certain types of recurrent or metastatic breast cancer.

Last year for the first time, the Food and Drug Administration (FDA) approved a Positron Emission Tomography (PET) nuclear medicine imaging agent, Cerianna, which detects estrogen receptor (ER) positive lesions to help determine treatment protocols for patients with recurrent or metastatic breast cancer.

“This new imaging is significantly more specific than other imaging agents and is a valuable additional tool in our toolbox,” said Louis Mazzarelli, MD, director of diagnostic radiology at L+M and Westerly hospitals. “If a PET scan identifies disease, we can aid our Smilow Oncology team in developing a more personalized treatment plan, which can significantly alter outcome for our patients.”

“This is a totally different approach to medicine,” he said. “Once in the body, the radiotracer seeks abnormalities specifically related to estrogen positive breast cancer. If these are present within lymph nodes or within the body otherwise, the treating team can use that lesion roadmap to develop an optimal care plan.”

The radiotracer is injected during a PET scan and highlights the presence of cancer in organs and tissue. In particular, it provides visual detection of ER positive lesions. The process takes about 80 minutes before radiologists are able to review the images.

It is estimated that 1 in 12 women in the United States will develop some form of breast cancer and that over a quarter-million breast cancer diagnoses are made each year. The American Cancer Society estimates that roughly two out of every three breast cancer cases are hormone receptor positive.

“We are excited to offer this new advanced imaging technique which provides a more specific understanding of the extent of disease in a subset of our patients with breast cancer,” said Robert D. Legare, MD, medical director, Smilow Cancer Hospital Care Center at Waterford. “Our radiologists are bringing advanced diagnostic techniques to our community, offering innovation to help us serve our patients in the best possible manner.

“The use of this radiotracer is a significant step forward in nuclear medicine that will allow physicians to more precisely treat their patients based on the most accurate information” said Dr. Mazzarelli. “While we have made significant strides in breast cancer treatment for the general population, we can now further customize treatment one patient at a time, bringing the greatest of care to our patients.”

Lawrence + Memorial Hospital, a member of Yale New Haven Health, is a non-profit, 308-bed general and acute care hospital providing patient care to medical, surgical, pediatric, psychiatric and obstetrical patients in southeastern Connecticut and southern Rhode Island since 1912. Lawrence + Memorial offers cardiac acute, step-down and rehabilitation programs and is the only eastern Connecticut hospital that performs emergency and elective angioplasty. www.lmhospital.org

Similar Articles

2/20/2024

Yale New Haven Health announces Pamela Sutton-Wallace as the new president of Yale New Haven Health

New Haven, CT (February 20, 2024) – Yale New Haven Health today announced that Pamela Sutton-Wallace has been promoted to president of Yale New Haven Health.

2/14/2024

Yale New Haven Health announces Katherine Heilpern, MD, as the new president of Yale New Haven Hospital

New Haven, CT (February 15, 2024) – Today, Yale New Haven Health announced the appointment of Katherine Heilpern, MD, FACEP, as the new president of Yale New Haven Hospital, the Health System’s flagship hospital, effective March 11.

2/6/2024

Yale New Haven Health retail pharmacy to open at Lawrence + Memorial Hospital

NEW LONDON, CT (Feb. 6, 2024) Yale New Haven Health (YNHHS) cut the ribbon on a state-of-the-art retail pharmacy in the main lobby of Lawrence + Memorial (L+M) Hospital today, introducing integrated, personalized medication care for patients, employees and the surrounding community.